Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients

(2015) Marina Bagnoli et al.   Oncotarget

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

(2014) Guoyan Liu et al.   JOURNAL OF PATHOLOGY

MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer

(2014) Yan Sun et al.   JOURNAL OF PATHOLOGY

Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation

(2014) P. Gasparini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer

(2013) Da Yang et al.   CANCER CELL

Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition

(2013) Kenji Sakogawa et al.   CANCER SCIENCE

Identification of miRNA modulators to PARP inhibitor response

(2013) Sari Neijenhuis et al.   DNA REPAIR

Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer

(2013) Min Zhao et al.   Molecular BioSystems

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

(2012) Kelly L. Bolton   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics

(2011) Zhengguan Yang et al.   BIOCHEMICAL PHARMACOLOGY

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

(2011) Zhiyong Mao et al.   CELL CYCLE

MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells

(2011) Jin Lu Tong et al.   FEBS LETTERS

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

(2011) E Kiyohara et al.   GENE THERAPY

Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer

(2011) Da Yang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Unraveling the mechanism of BRCA2 in homologous recombination

(2011) William K Holloman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth

(2011) K L Streicher et al.   ONCOGENE

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs

(2011) Steve Quiros et al.   PLoS One

The role of miR-506 in transformed 16HBE cells induced by anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide

(2011) Yao Zhao et al.   TOXICOLOGY LETTERS

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non-Small-Cell Lung Cancer Cells

(2010) M.-S. Tsai et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Purified human BRCA2 stimulates RAD51-mediated recombination

(2010) Ryan B. Jensen et al.   NATURE

Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model

(2009) Janaiah Kota et al.   CELL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assembly of checkpoint and repair machineries at DNA damage sites

(2009) Michael S.Y. Huen et al.   TRENDS IN BIOCHEMICAL SCIENCES

The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

(2008) Désirée Bonci et al.   NATURE MEDICINE

Suppression of non-small cell lung tumor development by the let-7 microRNA family

(2008) M. S. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA